Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 1, 2013, Pages 74-80

  Del Campo, J A ^a   Ampuero, J ^a   Rojas, L ^a   Conde, M ^b   Rojas, A ^a   Maraver, M ^a   Millan R ^a   Garcia Valdecasas M ^a   Garcia Lozano J R ^b   Gonzalez Escribano M F ^b   Romero Gomez M ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; FIBROSIS; GENETIC POLYMORPHISM; GENOTYPING TECHNIQUE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; VIRAL CLEARANCE; VIRUS DETECTION; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BLOOD GLUCOSE; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HEPATITIS C, CHRONIC; HUMANS; INSULIN; INSULIN RESISTANCE; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84870609448     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12113     Document Type: Article

References (21)

1. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, et al,. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
2. Eslam M, Aparcero R, Kawaguchi T, et al,. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011; 34: 297-305.
3. Deltenre P, Louvet A, Lemoine M, et al,. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol 2011; 55: 1187-94.
4. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
5. Asselah T, Essioux L, Marcellin P,. A chromosome 19 SNP (rs12979860) predicts outcome (EVR/SVR) in HCV patients treated with interferon, independent of pegylation or ribavirin. J Hepatol 2010; 52: 1180A.
6. Ogawa E, Furusyo N, Murata M, et al,. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. J Hepatol 2012; 57: 534-40.
7. Poordad F, McCone J, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
8. McCarthy JJ, Li JH, Thompson A, et al,. Replicated Association between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin. Gastroenterology 2010; 138: 2307-14.
9. Montes-Cano MA, García-Lozano JR, Abad-Molina C, et al,. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52: 33-37.
10. Stättermayer AF, Stauber R, Hofer H, et al,. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 344-350.
11. Sugiyama M, Tanaka Y, Wakita T, Nakanishi M, Mizokami M,. Genetic variation of the IL-28B promoter affecting gene expression. PLoS ONE 2011; 6: e26620.
12. Romero Gomez M,. Insulin resistance and sustained virological response in hepatitis C: from bench to bedside. Liver Int 2011; 31: 1-3.
13. Stättermayer AF, Rutter K, Beinhardt S, et al,. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol 2012; 57: 492-8.
14. Huang JF, Yu ML, Huang CF, et al,. The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy. Liver Int 2012; 32: 962-969.
15. Fattovich G, Covolo L, Bibert S, et al,. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 1162-72.
16. Pazienza V, Clément S, Pugnale P, et al,. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007; 45: 1164-71.
17. Ramcharran D, Wahed AS, Conjeevaram HS, et al,. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 2010; 52: 854-863.
18. Harrison SA, Rossaro L, Hu KQ, et al,. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010; 52: 864-874.
19. Clark PJ, Thompson AJ, Zhu M, et al,. Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. J Viral Hepat 2012; 19: 332-40.
20. Serfaty L, Forns X, Goeser T, et al,. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut 2012; 61: 1473-80.
21. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.